Pieris lays off most staff after AstraZeneca pulls out of partnership
Pieris has also begun the process of exploring strategic alternatives. That could include a merger or acquisition or an asset sale.
Pieris Pharmaceuticals, Inc., a biotechnology company, discovers and develops biotechnological applications. The company focuses on the development of its 4-1BB bispecifics immuno-oncology (IO) programs. Its clinical pipeline consists of IO bispecifics, including S095012 (PRS-344), a bispecific Mabcalin compound targeting PD-L1 and 4-1BB in partnership with Les Laboratoires Servier and Institut de Recherches Internationales Servier; SGN-BB228 (PRS-346), a CD228 x 4-1BB bispecific antibody-Anticalin compound targeting CD228 and 4-1BB in partnership with Pfizer Inc.; and BOS-342 (PRS-342), a GPC3 x 4-1BB bispecific Mabcalin compound targeting GPC3 and 4-1BB in partnership with Boston Pharmaceuticals, which are in phase 1 studies. The company was founded in 2001 and is headquartered in Boston, Massachusetts.
| 17.01 | |
| 16.53 | |
| - | |
| 17.9597 | |
| 16.5101 | |
| 6.2-41.784 | |
| 22 555 K | |
| 1 320 K | |
| 40 927 K | |
| -3.9547 | |
| 0.682 |
No long-term obligations. The minimum period is one month only. No wait. You get an API key with instructions in a few seconds right after subscription.
Pieris has also begun the process of exploring strategic alternatives. That could include a merger or acquisition or an asset sale.
Pieris Pharmaceuticals’ PIRS shares were up almost 12% on Jul 18, after management announced strategic update in light of the recent events that have impacted its respiratory franchise. In order to ...
Our 24/7 support would be happy to assist you via chat or email:
support@eodhistoricaldata.comVisit also: